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HORMONE REPLACEMENT THERAPY IN THE WAKE OF
THE WOMEN'S HEALTH INITIATIVE STUDY: AN
OPPORTUNITY TO REEXAMINE THE LEARNED
INTERMEDIARY DOCTRINE
INTRODUCTION
Litigation resulting from recent data published about the
adverse risks of hormone replacement therapy has brought the
learned intermediary doctrine to the surface of products liability
jurisprudence. On July 9, 2002, the Women's Health Initiative
(WHI) of the National Institute of Health (NIH) announced that it
was stopping its massive study after five years of hormone replace-
ment therapy use because the risks associated with the drugs
greatly exceeded the benefits.' This news prompted more bad press
about hormone replacement therapies as well as litigation by
women against Wyeth, the manufacturer of Prempro, a popular
hormone replacement drug.2
Hormone replacement therapy is the use of conjugated estro-
gens, progesterone, and sometimes androgen to substitute the
body's loss of natural hormones in women who have undergone
menopause.3 Estrogen replacement therapy, of which Wyeth's drug
Premarin is a popular example, is intended for the same use in
women who have undergone a surgical removal of their uterus.4
In one of the resulting cases that plaintiffs have brought
against Wyeth for its manufacturing of Prempro, the Pennsylvania
Court of Common Pleas, among other claims, dismissed the plain-
tiffs claim under the Pennsylvania Unfair Trade Practices and
Consumer Protection Law (UTPCPL) for failure to warn of the
drug's risks.' The court concluded that the learned intermediary
doctrine barred recovery and held that there should be no exception
for drugs that are promoted directly to consumers through advertis-
ing.6 It is the only court thus far to have reached a decision in such
a case against Wyeth.
The learned intermediary doctrine, first pronounced approximately
forty years ago, precludes plaintiffs from holding pharmaceutical com-
panies liable for failure to warn consumers of drugs' adverse effects if
1. Tobias Millrood, The Rise and Fall of Hormone Therapy, 39 TRIAL 42, 42 (2003).
2. Id.
3. Id.
4. Id.
5. Albertson v. Wyeth Inc., 2003 WL 21544488, at *10 (Pa. Ct. C.P. July 8, 2003).
6. Id.
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the manufacturers have adequately warned the prescribing physi-
cians.' The learned intermediary doctrine essentially states that
pharmaceutical companies have no duty to warn consumers of the
possible risks and side effects of drugs because it is the duty of the
doctor prescribing the drugs to relay the side effects to consumers.'
'The overwhelming majority of states have adopted the learned
intermediary doctrine."9 In the last few years, however, a number
of courts have recognized exceptions to the doctrine for particular
types of pharmaceutical drugs.' ° Several courts have recognized an
exception with mass immunizations and drugs that have Food and
Drug Administration (FDA) mandated warnings such as contracep-
tives." One court found an exception because the drug had been
overly promoted by the manufacturer. 12 In 1999, another court
found that direct-to-consumer advertising barred the learned
intermediary doctrine from shielding pharmaceutical companies
from a negligent consumer warning claim.'3
Upon examining the current laws and arguments for and against
the learned intermediary doctrine, this note argues that the failure
of hormone replacement therapy's manufacturers to adequately warn
consumers directly of the risks of hormone replacement therapy
necessitates the expansion of the exception for direct-to-consumer
advertising. In the alternative, it is argued that hormone replacement
therapy fits into the exception for contraceptives.
Part I provides a brief summary of background information on
estrogen and hormone replacement therapy, with an emphasis on
how Wyeth was able to amass significant numbers of female
prescribers through its advertising campaign. The summary will
7. James Ottavio Castagnera & Richard Ryan Gerner, The Gradual Enfeeblement of the
Learned Intermediary Rule and the Argument in Favor of Abandoning It Entirely, 36 TORT &
INS. L.J. 119, 122 (2000).
8. Dabney J. Carr, IV & Bryony H. Bowers, Recent Developments in Learned
Intermediary Doctrine, 31 THE BRIEF 20, 20 (2002).
9. In re Meridia Prods. Liab. Litig., 328 F. Supp. 2d 791 (N.D. Ohio 2004) (citing Thorn
v. Bristol Myers Squibb Co. 353 F.3d 848, 852 (10th Cir. 2003)) ("The Tenth Circuit recently
found that 44 states, plus Wyoming, had adopted the learned intermediary doctrine in
prescription drug cases.").
10. Richard Ausness, Will More Aggressive Marketing Practices Lead to Greater Tort
Liability for Prescription Drug Manufacturers? 37 WAKE FOREST L. REV. 97, 110 (2002); see
also Perez v. Wyeth Labs. Inc., 734 A.2d 1245 (N.J. 1999); MacDonald v. Ortho Pharm. Corp.,
475 N.E.2d 65 (Mass. 1985); Odgers v. Ortho Pharm. Corp., 609 F. Supp. 867 (E.D. Mich.
1985); Stephens v. G.D. Searle & Co., 602 F. Supp. 379 (E.D. Mich. 1985); and Lukaszewicz
v. Ortho Pharm. Corp., 510 F. Supp. 961 (E.D. Wis. 1981).
11. Ausness, supra note 10, at 111-13.
12. Stevens v. Parke, Davis & Co., 507 P.2d 653, 663 (Cal. 1973) (concluding that the jury
could find that the manufacturer's over-promotion of the drug influenced physicians so that
over-prescription was a foreseeable consequence).
13. Perez, 734 A.2d. at 1257.
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culminate with a description of the recent class action lawsuit filed
in Pennsylvania and the judge's decision that the learned inter-
mediary doctrine barred recovery by the plaintiffs on a negligent
warning claim. Part II discusses the learned intermediary doctrine,
established in 1966 and still followed in most jurisdictions, along
with the few exceptions that have been carved in the last several
years. Part III considers the pros and cons of the doctrine and
argues that the hormone replacement therapy disaster demon-
strates why the learned intermediary doctrine should be overruled.
Part IV argues that hormone replacement therapy should fall under
the direct-to-consumer advertising exception as the extensive ad-
vertising campaign by Wyeth that made Premarin and Prempro
bestsellers for several years provides more support for the holding
in Perez v. Wyeth Laboratories Inc.4 Realizing that courts are appre-
hensive to overrule the learned intermediary doctrine by further
expanding the exception for direct-to-consumer advertising, Part V
argues that, at a minimum, hormone replacement therapy should
fall under the exception that has developed for contraceptives.
I. THE NOT-SO-WONDERFUL WONDER DRUG FOR
POST-MENOPAUSAL WOMEN
Women have been wronged by pharmaceutical manufacturers
once again. Hormone replacement therapies are not the first
prescription drugs or devices to be found harmful to women after
being marketed to consumers.15 In fact, the Dalkon Shield and the
Norplant contraceptive device were not only found to cause harmful
adverse effects in the women who used the devices, but both were
designed to control female hormones and reproduction." Addition-
ally, between 1997 and 2001, of the ten drugs that were withdrawn
from the market by the FDA, eight were withdrawn because of
adverse effects discovered in women, even though the drugs were
intended for use by women and men.1
7
14. Id. at 1251 (holding that the learned intermediary doctrine did not apply to drugs (in
this case the contraceptive Norplant) directly advertised to consumers).
15. See Anna Birenbaum, Shielding the Masses: How Litigation Changed the Face of Birth
Control, 10 S. CAL. REv. L. & WOMEN'S STUD. 411 (2001) (discussing the litigation concerning
the Dalkon Shield and the Norplant contraceptive device).
16. Id. at 411-13.
17. Letter from Janet Heinrich, Director of the General Accounting Office, to The
Honorable Tom Harkin, The Honorable Olympia J. Snowe, The Honorable Barbara A.
Mikulski, The United States Senate, and The Honorable Henry A. Waxman, The House of
Representatives (Jan. 19, 2001) (on file with the General Accounting Office, GAO-01-286R),
available at http://www.gao.gov/new.items/d01286r.pdf.
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The announcement by the NIH that it would be stopping the
WHI study on the hormone replacement therapy Prempro early
because of the high incidence of risks to women taking the drug, was
the beginning of a series of published studies releasing data on the
risks of hormone replacement therapy." The study, following 16,608
women, was stopped a little after five years, because the risks
associated with Prempro exceeded the benefits. 9 Although the study
found a 37% reduction in colorectal cancer, 33% less vertebral and
hip fractures, and 24% fewer total fractures, the women taking
Prempro in the study had 41% more strokes than those taking the
placebo, 29% more developed cardiovascular disease, and 26% more
women developed breast cancer.2 ° Data subsequently released has
indicated that long-term use of estrogen-only replacement therapy
significantly increases a woman's chance of developing ovarian
cancer,2 and starting hormone replacement therapy at or after age
sixty-five may also significantly increase the risk of developing
Alzheimer's disease.22 Furthermore, data has shown that hormone
replacement therapy may not even relieve the menopausal symp-
toms for which the drug is intended to be prescribed, such as
sleeplessness, lack of vitality, sexual dissatisfaction, or depression.23
Many post-menopausal women were shocked by this data as
Prempro had been heavily promoted by Wyeth and taken by
millions of women for years as a result of such marketing.24 The
plaintiffs in Albertson v. Wyeth Inc., a recent case against Wyeth for
its manufacturing of Prempro, cite that immediately prior to the
recent studies being released, 38% of post-menopausal women were
using either hormone or estrogen replacement therapy, and of those
women, six million were taking Prempro, the most popular hormone
or estrogen replacement therapy drug in the United States.25
Wyeth's Premarin was first patented in 1942 to "cure" the physical
18. Millrood, supra note 1, at 42. See, e.g., James V. Lacey, Jr., et al., Menopausal
Hormone Replacement Therapy and Risk of Ovarian Cancer, 288 JAMA 321, 324 (2002);
Jacques E. Rossouw, et al., Risks and Benefits of Estrogen Plus Progestin in Healthy
Postmenopausal Women, 288 JAMA 321, 322 (2002); Sally A. Shumaker et al., Estrogen Plus
Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal
Women, 289 JAMA 2651 (2003).
19. Millrood, supra note 1, at 43-44.
20. Id. at 44; see also Rossouw, supra note 18, at 321-22; Writing Group for the Women's
Health Initiative, Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal
Women Principal Results from the Women's Health Initiative Randomized Controlled Trial,
288 JAMA 321, 321-22 (2002).
21. Lacey, supra note 18, at 334.
22. Millrood, supra note 1, at 44.
23. Id.
24. Id. at 43.
25. Albertson v. Wyeth Inc., 2003 WL 21544488, at *1 (Pa. Ct. C.P. July 8, 2003).
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side effects of menopause.26 In 1966, Robert Wilson, a Brooklyn
gynecologist, touted Premarin, a predecessor to Prempro, as the
"cure" for the "tragedy of menopause" that "preserves the strength
of her bones, the glow of her skin, the gloss of her hair" and "makes
women adaptable, even-tempered, and generally easy to live with"
in his published best-seller Feminine Forever.27 Considering that
Premarin could only be prescribed for women, it is remarkable that
by the mid-1970s, it was the fifth most widely prescribed drug in the
country.28
Soon thereafter, Wyeth learned that its hormone replacement
therapy could also help to prevent osteoporosis, 2 9 and in 1985, Wyeth
launched a campaign to educate women about osteoporosis and
assisted in the creation of the National Osteoporosis Foundation."0
While promoting awareness of osteoporosis, Wyeth simultaneously
marketed its hormone replacement therapy, claiming that the
therapy could also prevent heart disease without the risk of causing
stroke and cancer.3' This marketing campaign proved enormously
successful. Between the years 1990 and 1995, Premarin was the
most frequently prescribed drug in the United States.3 2 Finally, in
1995, Wyeth's Prempro was approved by the FDA and was the first
pill that combined estrogen and progestin.33 The WHI Study in 2002
ended Wyeth's hopes of reaping greater profits from Prempro,
however. Instead, it resulted in a series of lawsuits.34
Various women filed suits against Wyeth with claims such as
negligence in producing a defective product; failure to provide
adequate warnings and labels; misleading women and doctors to
believe that menopause was a disease while exaggerating the drugs'
benefits;3" fraud; and breach of warranty. 6 Lawsuits against Wyeth
have been filed in Pennsylvania, Ohio,3" Maryland," Arkansas, and
26. Milirood, supra note 1, at 43.
27. Id. See generally ROBERT A. WILSON, FEMININE FOREVER (1968).
28. Millrood, supra note 1, at 43.
29. Osteoporosis is a disease in which the bones become extremely porous and subject to
fracture. Id.
30. Id.
31. Id.
32. This is all the more remarkable when one considers that only half the population was
targeted. Id.
33. Id.
34. Id. at 45.
35. Sharon Coolidge, Hormone Drug Basis for Lawsuit, CINCINNATI ENQUIRER, May 21,
2004, at 1D.
36. RedNova.com, Lawsuit Filed by Baltimore Woman Blaming Cancer on Hormone Drug,
http://www.rednova.com/news/displayfid=151998.
37. Coolidge, supra note 35.
38. RedNova.com, supra note 36 (describing a recent claim by a woman in Maryland
against Wyeth).
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California,3" among other states, 4° and there are other lawsuits in
the process of being filed.41 Fortunately for Wyeth, one court
recently denied class certification to a group of women who had
taken hormone replacement therapy for at least one year prior to
2002.42
Thus far, the Pennsylvania Court of Common Pleas is the only
court to have reached a decision in a case brought against Wyeth
for its advertising, promotion, and sale of Premarin or Prempro.4'
Plaintiffs filed the following claims against Wyeth for its manufac-
turing and promotion of Prempro: negligence in medical monitoring;
unjust enrichment; violation of the UTPCPL; breach of fiduciary
duty; and fraud.44 Plaintiffs argued that the UTPCPL applied to
prescription drug manufacturers and that a limited exception
should be made to the learned intermediary doctrine for manufac-
turers who engage in direct-to-consumer advertising. 45 The court
rejected this argument and held that the learned intermediary
doctrine barred their recovery under the UTPCPL.46 Otherwise, the
court explained, a drug manufacturer would be forced to guarantee
that a prescription drug was entirely safe. 47 This, the court held,
would be impossible, for "some prescription drugs by their very
nature, can never be made safe."4
II. THE LEARNED INTERMEDIARY DOCTRINE AND ITS EXCEPTIONS
A manufacturer is generally required "to warn consumers of
danger[s] associated with the use of its product to the extent the
39. See In re Prempro Prod. Liab. Litig., 254 F. Supp. 2d 1366 (W.D. Va. 2003) (granting
a motion by the Judicial Panel on Multidistrict Litigation in the Central District of California
for consolidation of cases to the Eastern District of Arkansas).
40. Id. at 1367 n.1 (noting that the Judicial Panel on Multidistrict Litigation was informed
of other related actions in the Southern District of Florida, Eastern District of Louisiana,
Northern and Southern Districts of Illinois, Eastern District of New York, Northern District
of West Virginia, and the District of Puerto Rico).
41. See, e.g., The Williamson Law Firm, Hormone Replacement Therapy or "HRT"
Litigation, http://www.eawlaw.comcurrentevents.htm (stating the intention of the Edward
A. Williamson Law Firm to file "nearly 100 cases for clients who have suffered blood clotting,
breast and ovarian cancers or Lupus from the ingestion of the drug manufactured by Wyeth
called Prempro").
42. Albertson v. Wyeth Inc., 2005 WL 1048779, at *1 (Pa. Ct. C.P. Apr. 26, 2005).
43. Albertson v. Wyeth Inc., 2003 WL 21544488, at *12 (Pa. Ct. C.P. July 8, 2003).
44. Id. at *5.
45. Id. at *11.
46. Id. at *9-*10.
47. Id. at *10.
48. Id.
HORMONE REPLACEMENT THERAPY
manufacturer knew or should have known of the danger[s] . 49 The
learned intermediary doctrine is an exception to a manufacturer's
duty to warn for one type of industry: pharmaceutical manufactur-
ers. The learned intermediary doctrine shields them from any
liability so long as the manufacturer sufficiently warns the prescrib-
ing physicians of the drug's risks and side effects.5 ° The doctrine is
based on the rationale that the prescribing physician acts as the
'learned intermediary" between the drug company and the con-
sumer because he or she assesses the patient's condition along with
the drug's risks while taking into account the patient's needs.5'
Although crafted in 1966,52 the learned intermediary doctrine
continues to be followed by the overwhelming majority of courts
today, with a few notable exceptions that will be highlighted in
detail after a brief discussion of the case law upholding this
doctrine.
The learned intermediary doctrine was first pronounced in 1966
by the Eighth Circuit. In the case of Sterling Drug, Inc. v. Cornish
the court explained, "If the doctor is properly warned of the
possibility of a side effect in some patients, and is advised of the
symptoms normally accompanying the side effect, there is an
excellent chance that injury to the patient can be avoided."53
Whereas pharmaceutical companies were, and still are, held to a
duty to only inform the doctors,54 the burden shifted to the doctors
to warn patients of the risks and side effects of every drug pre-
scribed.55 This burden was in addition to the physician's traditional
role of advising patients about how and when to take the drug. It
thus became the duty of the doctor prescribing the medication to be
fully aware of the characteristics of the drug, the proper amount of
the drug to be administered, and the different medications the
patient was taking.5
6
Recognizing changes in the physician-patient relationship and
how prescription drugs are marketed to consumers, a few jurisdictions
49. Edwards v. Basel Pharm., 933 P.2d 298, 300 (Okla. 1997) (citing Kirkland v. Gen.
Motors, 521 P.2d 1353 (Okla. 1974)).
50. Ausness, supra note 10, at 103-04.
51. Edwards, 933 P.2d at 300 (citing Cunningham v. Pfizer & Co., Inc., 532 P.2d 1377,
1381 (Okla. 1975)).
52. Sterling Drug, Inc. v. Cornish, 370 F.2d 82 (8th Cir. 1966).
53. Id. at 85.
54. Susan A. Casey, Laying an Old Doctrine to Rest: Challenging the Wisdom of the
Learned Intermediary Doctrine, 19 WM. MITCHELL L. REV. 931, 938 (1993).
55. Ausness, supra note 10, at 107-08.
56. See William M. Brown, Ddjd Vu All Over Again: The Exodus from Contraceptive
Research and How to Reverse It, 40 BRANDEIS L.J. 1, 21 (2001).
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have found exceptions to the learned intermediary doctrine.5 7 First,
several jurisdictions have ruled that patients are not precluded from
holding the manufacturers of mass immunizations liable for the
failure to warn consumers of the risks and side effects.58 In Davis v.
Wyeth Laboratories Inc., the court based its reasoning on the fact that
mass immunizations, such as the polio vaccine, are often given
without a physician present.59 Thus, there is often no physician to act
as an intermediary.'
Another category of prescription drugs for which courts have
held manufacturers liable for their failure to warn consumers are
drugs for which the FDA has mandated manufacturers to provide
warnings directly to consumers.61 Several states have recognized
this exception. Most cases have involved contraceptives and
contraceptive devices, while Oklahoma has adopted the exception
for nicotine patches." Before discussing this category, it should be
noted that courts are split as to whether merely complying with
FDA regulations precludes consumers from holding manufacturers
of drugs liable.63 With respect to the learned intermediary doctrine,
several courts have held that merely complying with FDA minimum
standards is not necessarily sufficient to relieve drug manufacturers
of liability.'
In Stephens v. G.D. Searle & Co. in 1985, a court held for the
first time that Michigan law requires pharmaceutical drug manufac-
turers of oral contraceptives to warn patients who are taking the
drugs for contraceptive purposes directly of the risks and side effects
57. See Casey, supra note 54, at 939-47 (discussing case law supporting the vaccine, oral
contraceptives, and intrauterine device exceptions).
58. See, e.g., Edwards v. Basel Pharm., 933 P.2d 298, 301 (Okla. 1997) (discussing the
vaccination exception and its rationale as well as Oklahoma and Nevada case law); Allison
v. Merck & Co., Inc., 878 P.2d 948 (Nev. 1994).
59. Davis v. Wyeth Labs., Inc., 399 F.2d 121 (9th Cir. 1968); see also Samuels v. American
Cyanamid Co., 495 N.Y.S.2d 1006 (N.Y. Sup. Ct. 1985) (holding that a pharmaceutical
company had a duty to warn "travel" vaccine recipients of adverse side effects).
60. Davis, 399 F.2d at 131.
61. Ausness, supra note 10, at 112-13; see also McKee v. Moore, 648 P.2d 21, 24 (Okla.
1982) (holding that a physician has the duty to warn patients of drug side effects instead of
the manfacturer unless FDA regulations require the manufacturer to warn the consumers
directly through drug labeling).
62. Edwards, 933 P.2d at 301 (discussing cases involving contraceptives that support an
exception to the learned intermediary doctrine if the FDA requires the manufacturers to
directly warn consumers, and concluding that the same rationale should be extended beyond
contraceptives and include nicotine patches).
63. Ausness, supra note 10, at 113.
64. Edwards, 933 P.2d at 301-02; see also Brochu v. Ortho Pharm. Corp., 642 F.2d 652 (1st
Cir. 1981); MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65 (Mass. 1985); McEwen v. Ortho
Pharm. Corp., 528 P.2d 522 (Or. 1974); Mazur v. Merck & Co., 742 F. Supp. 239, 247 (E.D. Pa.
1990).
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of the contraceptives.65 It found that the learned intermediary
doctrine should not apply to cases involving oral contraceptives
because contraceptives are not like therapeutic, diagnostic, and
curative drugs.' The court laid out several reasons for its watershed
decision. It noted that because there is no assessment of medical
need for a patient seeking contraceptives, there is not complete
reliance on the physician's selection of an appropriate method of
contraception as would be the case were a doctor prescribing and
treating an illness. 7 Moreover, the focus with oral contraceptives is
on patient choice rather than the doctor's advice.68 Generally, before
a patient goes to the doctor the patient has already decided that she
wants to take oral contraceptives.69 The court concluded that a
direct warning to the patient was required due to the primary role
the patient's choice plays in the prescription.7 °
The court also noted that the nature of the physician-patient
relationship is different in the case of oral contraceptives because a
woman can continually get refills without consulting her physician;
thus, she is taking the prescription without any assessment of its side
effects.71 Finally, the court observed that pharmaceutical manufac-
turers aggressively advertise oral contraceptives to women.72 As a
result of such advertising, women believe that oral contraceptives
are the most effective form of birth control and use this information
to request them from their physicians.7" The court further observed
that doctors acquiesce to the women's demands by prescribing the
oral contraceptives for such women.74
Decided two weeks after Stephens v. G.D. Searle & Co., the
Supreme Judicial Court in Massachusetts, the state's highest court,
echoed the "peculiar characteristics" of oral contraceptives, to in-
clude the doctor's passive role and minimal oversight of side effects
to justify a manufacturer's duty to warn in MacDonald v. Ortho
65. Stephens v. G.D. Searle & Co., 602 F. Supp. 379, 380-81 (E.D. Mich. 1985) (citing In
re Certified Questions, Odgers v. Ortho Pharm. Corp., Grainger v. Sandoz Pharm., 358
N.W.2d 873, 878 (Mich. 1984)) (Boyle, J., dissenting) ('[Iln addition to its duty to warn the
prescribing physician, the manufacturer of an oral contraceptive has a duty to warn the user
directly of known hazards.").
66. Id.
67. Id.
68. Id.
69. Id.
70. Id. at 381.
71. Id.
72. Id. at 380.
73. Id.
74. Id. at 380-81.
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Pharmaceuticals Corp.75 It also reasoned that oral contraceptives
are subject to such extensive federal regulation by the FDA that
a woman who takes such drugs does so with a level of informed
consent.7" Odgers v. Ortho Pharmaceuticals Corp., also decided in
1985, held that the learned intermediary doctrine does not apply for
oral contraceptives as well.77 In addition to the reasons cited in
MacDonald and Stephens, the court noted that one of the policies
behind the learned intermediary doctrine was to prevent patients
from refusing to take prescription drugs by becoming unnecessarily
afraid of the drugs after reading the warnings.78 It therefore
concluded that this problem does not exist with oral contraceptives
as it is better for a woman to be informed since there are so many
birth control options.79
With respect to intrauterine devices for women, the courts are
split. The Fourth and Sixth Circuits upheld the learned intermedi-
ary doctrine as applied to intrauterine devices in 1987 and 1992
respectively. 0 In 1989, however, the Eighth Circuit held that the
learned intermediary doctrine should not apply to intrauterine
devices. The court reasoned that they are unlike other prescription
drugs and more like oral contraceptives because the prescribing
doctor does not "make an intervening, individualized medical
judgment in the birth control decision.""
The final exception that has been carved from the learned
intermediary doctrine is for prescription drugs that undergo direct-
to-consumer advertising.8 Over twenty-five years before the New
75. 475 N.E.2d 65, 69 (Mass. 1985).
76. Id. at 69-70.
77. Odgers v. Ortho Pharm. Corp., 609 F. Supp. 867, 878-79 (E.D. Mich. 1985).
78. Id. at 878.
79. Id.
80. See Odom v. G.D. Searle & Co., 979 F.2d 1001 (4th Cir. 1992); Beyette v. Ortho Pharm.
Corp., 823 F.2d 990 (6th Cir. 1987).
81. Hill v. Searle Labs., 884 F.2d 1064, 1070 (8th Cir. 1989). In 2000, the Texas Court of
Appeals refused to find an exception to the learned intermediary doctrine for contraceptives.
See Wyeth-Ayerst Labs. Co. v. Medrano, 28 S.W.3d 87 (Tex. App. 2000).
82. Bradford B. Lear, The Learned Intermediary Doctrine in the Age of Direct Consumer
Advertising, 65 Mo. L. REV. 1101, 1108-09 (2000). For more information on direct-to-consumer
advertising and the learned intermediary doctrine, see Tim S. Hall, Bypassing the Learned
Intermediary: Potential Liability for Failure to Warn in Direct-to-Consumer Prescription Drug
Advertising, 2 CORNELL J.L. & PUB. POL'Y 449 (1993); Jack B. Harrison & Mina J. Jefferson,
"[S]ome [A]ccurate [Ilnformation is [Bietter than [N]o [Information [Alt [All" Arguments
Against an Exception to the Learned Intermediary Doctrine Based on Direct-to-Consumer
Advertising, 78 OR. L. REV. 605 (1999); Caroline L. Nadal, The Societal Value of Prescription
Drug Advertisements in the New Millennium: Targeted Consumers Become the Learned, 9 J.L.
& POL'Y 451 (2001); Yonni D. Fushman, Case Comment, Perez v. Wyeth Labs., Inc.: Toward
Creating a Direct-to-Consumer Advertisement Exception to the Learned Intermediary Doctrine,
80 B.U. L. REv. 1161 (2000); Amy D. White, Note, The Mass Marketing of Prescription Drugs
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Jersey Supreme Court decision in 1999, the California Supreme
Court held pharmaceutical companies liable for over-promotion of
their prescription drugs by representatives.83 The court concluded
that the pharmaceutical company had "so water[ed] down" its drug
warnings to doctors through its promotion of the drugs, by a
vigorous sales program, that doctors effectively disregarded the
warning.8 4 In Perez v. Wyeth Laboratories Inc., the New Jersey
Supreme Court held that the learned intermediary doctrine is
inapplicable when prescription drugs are directly marketed to the
consumer.8 5 A rebuttable presumption exists that when the manu-
facturer complies with FDA advertising, labeling, and warning
requirements, the manufacturer has satisfied its duty to warn the
consumer about the potentially harmful side effects of its product.8 6
The court further held, however, that when the manufacturer has
advertised its drug directly to consumers, the role of the physician
in prescribing the drugs does not break the chain of causation for a
manufacturer's failure to warn the patient of harmful side effects.87
The Perez court noted that legal jurisprudence about medicine
is based on outdated notions that no longer exist of physicians who
make house calls, neighborhood pharmacies, and drug companies
who advertise only to physicians.88 Its first reason for rejecting the
learned intermediary doctrine as applied to prescription drugs that
are directly marketed to consumers was that the decision to take the
prescription drug is no longer only one of medical judgment.8 9
Second, physicians spend less time per patient because of managed
care, so they do not have the time to detail to each patient all of
the adverse side effects of each medication. ° Third, manufacturer
advertising to consumers is very effective and undermines each of
the underlying premises of the learned intermediary doctrine.9 The
fact that such advertising is so effective showed that consumers are
"active in their health care decisions" and that prescription drugs
are not too complex for lay consumers to understand.92
and Its Effect on the Learned Intermediary Doctrine, 25 OKLA. CITY U. L. REV. 745 (2000);
Christopher Q. Pham, The Learned Intermediary Doctrine and DTC Advertising, 26 LA.
LAWYER 16 (2004).
83. Stevens v. Parke, Davis & Co., 507 P.2d 653 (Cal. 1973).
84. Id.
85. Perez v. Wyeth Labs. Inc., 734 A.2d 1245, 1247 (N.J. 1999).
86. Id. at 1259.
87. Id. at 1257-59.
88. Id. at 1247.
89. Id. at 1255.
90. Id.
91. Id. at 1255-56.
92. Id. at 1256.
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The court further stated that the argument that getting rid of
the learned intermediary doctrine would undermine the physician-
patient relationship is moot because that is already taking place as
a result of the direct-to-consumer advertising.9 With regard to
direct-to-consumer advertising by pharmaceutical companies, the
court stated, "It is one thing not to inform a patient about the
potential side effects of a product; it is another thing to misinform
the patient by deliberately withholding potential side effects while
marketing the product as an efficacious solution to a serious health
problem."94 The court noted that consumer protection is especially
important for "life-style" drugs which are heavily advertised,
elective, and can cause serious side effects.95
Just three months before the case was decided, the Fifth Circuit
refused to find such an exception,96 and since Perez, no court has yet
to follow its lead.97 Two courts have thus far addressed the direct-
to-consumer advertising exception to the learned intermediary
doctrine, declining to adopt Perez.9" One federal district court upheld
the learned intermediary doctrine and rejected the Perez rationale,
but after making choice-of-law determinations under Illinois and
New York law, the court did not grant summary judgment to
defendant manufacturer for those ten plaintiff consumers who had
the device implanted in New Jersey.99 Although another federal
district court may have found the Perez decision "well-reasoned," the
court declined to follow Perez because the court was forced to predict
Ohio state law."° The court believed that the Ohio Supreme Court
would not have followed Perez because no other court had done so
in the five years since Perez had been decided. 101
All other courts since Perez that have addressed the learned
intermediary doctrine without respect to direct-to-consumer adver-
tising have also upheld the learned intermediary doctrine. In 2001,
the Connecticut Supreme Court answered a certified question from
93. Id.
94. Id. at 1257.
95. Id.
96. In re Norplant Contraceptive Prods. Litig., 165 F.3d 374 (5th Cir. 1999).
97. In re Meridia Prods. Liab. Litig., 328 F. Supp. 2d 791, 811-12 n.19 (N.D. Ohio 2004)
(specifically rejecting plaintiffs argument to adopt the Perez court's direct-to-consumer
advertising because the federal court must apply state law under diversity jurisdiction and
no other state has adopted New Jersey's rationale).
98. See In re Norplant Contraceptive Prods. Liab. Litig., 215 F. Supp. 2d 795 (Tex. 2002);
In reMeridia, 328 F. Supp. 2d at 791.
99. In re Norplant, 215 F. Supp. 2d at 827-29.
100. In re Meridia, 328 F. Supp. 2d at 811-12 n.19 (involving a plaintiffs claim that Wyeth
failed to warn about the side effects of a diet drug which it had advertised to consumers).
101. Id.
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the Second Circuit Court of Appeals as to whether the learned
intermediary doctrine was controlling Connecticut law. °2 The state
supreme court held that the learned intermediary doctrine does
apply, but limited its holding to the facts of the case.' The facts
did not implicate any of the recognized exceptions.' °4 The Supreme
Court of Kentucky answered a certified question from the Sixth
Circuit as to whether the doctrine applies in Kentucky by adopting
the Restatement (Third) of Torts.0 5 In so doing, the court decided that
the learned intermediary doctrine should still apply in Kentucky,
but subject to exceptions that the court declined to address because
the facts of the case did not warrant discussion of the exceptions."
In 2004, the Eighth Circuit Court of Appeals held that, under North
Dakota law, the learned intermediary doctrine barred plaintiffs
action for damages against the pharmaceutical company for failure
to warn of a drug's side effects. 7
With respect to the pharmaceutical manufacturer's liability to
warn consumers of drugs' adverse side effects and risks, the drafters
of the Restatement (Third) of Torts chose to straddle the fence as to
whether the learned intermediary doctrine or its exceptions should
apply. 8 Section 8(d) states that a prescription drug manufacturer
must warn prescribing and other health care providers of the
foreseeable risks of harm associated with the drug or "the patient
when the manufacturer knew or had reason to know that no health
care provider would be in a position to reduce the risks of harm in
accordance with the instructions or warnings."'0 9 The drafters noted
that the Restatement left developing case law to resolve the
question of whether other exceptions to the learned intermediary
doctrine should be recognized. °
102. Vitanza v. Upjohn Co., 778 A.2d 829,830 (Conn. 2001). See Vitanza v. Upjohn Co., 271
F.3d 89 (2d Cir. 2001) for the Second Circuit's affirmation of the Connecticut Supreme Court
answer to the certified question.
103. Id.
104. Id. at 846-47 (implicating none of the exceptions because the drug was not heavily
marketed to consumers, was not a contraceptive, was not a mass immunization, and the FDA
did not require additional warnings directly to consumers).
105. Larkin v. Pfizer, Inc., 153 S.W.3d 758, 761 (Ky. 2005).
106. Id. at 765-70 (noting that the Restatement (Third) of Torts, Products Liability,
provides for some recognized exceptions to the doctrine and discusses the exceptions but
declines to apply those exceptions to Kentucky law, thus reserving the applicability of
exceptions to future Kentucky case law).
107. Ehlis v. Shire Richwood, Inc., 367 F.3d 1013 (8th Cir. 2004).
108. RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 8 (1998).
109. Id. § 8(d).
110. Edwards v. Basel Pharm., 933 P.2d 306, 306 (Okla. 1997) ("The Restatement has left
to developing case law to resolve whether other exceptions to the learned intermediary rule
should be recognized.").
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III. WHY Do WE STILL HAVE THE LEARNED INTERMEDIARY
DOCTRINE ANYWAY?
Although there are many reasons why scholars and courts
continue to uphold the learned intermediary doctrine, those reasons
are outweighed by the arguments for overturning the doctrine and
holding manufacturers directly liable to consumers for failing to
provide direct warnings. Those who support the learned intermedi-
ary doctrine continue to do so for several reasons. First, they believe
that the physician-patient relationship has remained unchanged
despite the advent of direct-to-consumer advertising.' This belief,
however, ignores evidence to the contrary. For better or for worse,
physicians are prescribing the drugs that patients are requesting.
As one study showed, eighty-six percent of patients who requested
Claritin received the drug from their physicians." 2 Additionally,
while doctors ultimately have control to write the prescriptions, they
must now spend time talking their patients out of drugs they have
seen advertised." 3 Learned intermediary doctrine supporters
further argue that requiring manufacturers to warn patients
undermines the physician-patient relationship." 4 Yet the evidence
shows the opposite. Pharmaceutical advertisements are undermin-
ing the physician-patient relationship because patients are not
going to doctors with symptoms but with drug names."5
Second, those in favor of the learned intermediary doctrine
claim that patients cannot sufficiently understand drug warnings
and that it is too difficult for pharmaceutical companies to explain
the risks of drugs on a level that consumers are able to
understand." 6 Nonetheless, patients are specifically asking their
doctors for drugs and are increasingly researching drugs on their
own. "7 Thus, it seems that if pharmaceutical companies took the
111. Harrison & Jefferson, supra note 82, at 619-22.
112. Elizabeth Powell-Bullock, Gaming the Hatch-Waxman System: How Pioneer Drug
Makers Exploit the Law to Maintain Monopoly Power in the Prescription Drug Market, 29 J.
LEGIS. 21, 42 (2002).
113. Carol Rados, Truth in Advertising: Rx Drug Ads Come of Age, FDA CONSUMER, July-
Aug. 2004, at 17, available at http://www.fda.gov/fdacfeatures/2004/404-ads.html.
114. Castagnera & Gerner, supra note 7, at 121; see also Perez v. Wyeth Labs. Inc., 734
A.2d 1245, 1255 (N.J. 1999); Casey, supra note 54, at 956.
115. Perez, 734 A.2d at 1256 (citing Casey, supra note 54, at 956) (footnotes omitted); see
also Castagnera & Gerner, supra note 7, at 120.
116. Ausness, supra note 10, at 137.
117. See Casey, supra note 54, at 956 (stating that consumers are more active in their
health care decisions today); Powell-Bullock, supra note 112, at 42 (providing an example that
patients were requesting Claritin from their physicians).
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time to make the warnings and contraindications easier for lay
persons to understand, patients would actually benefit.
Third, some scholars fear that if patients are exposed directly
to too many warnings by a manufacturer, the patients will not want
to use the drugs and will not seek medical help.118 There does not
seem to be any proof for this assertion as scholars who state this
argument use language that demonstrates mere speculation, such
as "might . .. scare off." ' In fact, the evidence shows that even
though patients have been warned of drugs' side effects and
warnings, whether generally in direct-to-consumer advertisements
or specifically by their physicians, they are still requesting the drugs
from their physicians.
20
Supporters of the learned intermediary doctrine also claim that
it is too difficult for manufacturers to adequately convey the warn-
ings and side effects to consumers. 12' They support this claim by
stating that radio or TV advertisements do not allot enough time to
satisfy all of the requirements for sufficient warnings according to
the FDA guidelines. 122 Furthermore, one claim is that it is difficult
to adequately convey the risks to consumers in print advertisements
because the warnings and contraindications are in small print on
the back. 23 Despite this claim, a 2001 study in a British medical
journal reported that ninety-eight percent of direct-to-consumer
print advertisements satisfy the FDA advertising guidelines and
fifty-one percent of direct-to-consumer advertisements provide even
more information than is required. 24 Also, "direct-to-consumer
warnings are no more burdensome than direct-to-consumer advertis-
ing."'25 It also logically follows that drug companies could design the
print advertisements so that the warnings and contraindications are
larger and not on the back.
Another reason against requiring manufacturers to directly warn
consumers is because it will subject manufacturers to greater liability,
118. Ausness, supra note 10, at 137.
119. Id.
120. See, e.g., Powell-Bullock, supra note 112, at 41-42 (explaining how those drugs that
are the most heavily advertised to consumers are prescribed the most frequently by
physicians and using Claritin as an example).
121. Ausness, supra note 10, at 137.
122. Id. (citing Michael C. Allen, Medicine Goes Madison Avenue: An Evaluation of the
Effect of Direct-to-Consumer Pharmaceutical Advertising on the Learned Intermediary
Doctrine, 20 CAMPBELL L. REv. 113, 129-30 (1997)).
123. Id.
124. Steven Woloshin et al., Direct-to-Consumer Advertisements for Prescription Drugs:
What Are Americans Being Sold? 358 THE LANcET 1141 (2001).
125. Castagnera & Gerner, supra note 7, at 143.
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thus increasing the number of lawsuits and, in turn, the manufactur-
ers' costs.'26 This phenomenon could then drive manufacturers away
from making the type of drugs for which an exception to the learned
intermediary doctrine has been created."' First, while it may be true
that discarding the learned intermediary doctrine for those drugs
which are directly advertised to consumers would potentially subject
pharmaceutical manufacturers to greater liability, this does not
necessarily mean that they would be subjected to greater lawsuits or
that their costs would increase. As the New Jersey Supreme Court
held in Perez, a manufacturer is entitled to a rebuttable presumption
that it complied with all of the FDA advertising regulations that are
required to warn a patient. 2 ' Thus, "FDA regulations serve as
compelling evidence that a manufacturer satisfied its duty" to warn
the consumers directly, just as the same presumption exists for
manufacturers who warn physicians.' 29 As noted, a 2001 study found
that ninety-eight percent of direct-to-consumer advertisements
comply with FDA regulations and fifty-one percent provide more
information than required, including "quantitative data" about the
frequency of the side effects listed.' ° Thus, barring the learned
intermediary doctrine when there is direct-to-consumer advertising
may not subject companies to liability. Expanded liability is therefore
not an unreasonable burden to place on manufacturers as they
currently have the ability to communicate easily with consumers 3 '
and are already forced to comply with FDA regulations.'3 2 It simply
provides a recourse for harmed consumers that does not currently
exist when manufacturers fail to comply with FDA regulations.
One scholar commented that when the exception to the doctrine
for oral contraceptives was created, there was an exodus by companies
from the manufacturing of contraceptives.'33 Thus, the same could be
possible once again if the doctrine were lifted for direct-to-consumer
advertisements. Since so many companies engage in direct-to-
consumer advertising, it is intuitively more difficult to believe that
companies would stop manufacturing drugs for which they engage in
such advertising, especially because those are the drugs that make the
126. Ausness, supra note 10, at 139.
127. See Brown, supra note 56, at 39-45.
128. Perez v. Wyeth Labs. Inc., 734 A.2d 1245, 1259 (N.J. 1999).
129. Id.
130. Woloshin'et al., supra note 124, at 1144.
131. Perez, 734 A.2d at 1255-56; see also Castagnera & Gerner, supra note 7, at 120.
132. Perez, 734 A.2d at 1257-59.
133. Brown, supra note 56, at 29-34.
HORMONE REPLACEMENT THERAPY
most profit.TM Because they do not want to forfeit the profits they are
making through advertising, it is possible that drug companies would
rather be more careful about what their advertisements conveyed to
consumers because of the possible liability.
The final argument in support of expanding the exceptions to
the learned intermediary doctrine, particularly in the context of
direct-to-consumer advertisements, is that the FDA already
regulates the promotion and labeling of prescription drugs.'35 This
ignores the reality that FDA regulations provide no recourse for
consumers who are harmed by inadequate warnings.'36 Not only do
they provide no recourse for harmed consumers, but data suggests
that the FDA is not sufficiently regulating prescription drug
advertising as it has instead been "captured by the industry it
regulates."'37 Additional liability for manufacturers may help make
manufacturers more conscious about messages that advertisements
send to consumers for fear of potential liability.
There are also several strong arguments in support of overturn-
ing the learned intermediary doctrine. Patients now play a much
more active role in their health care because of direct-to-consumer
advertising.3 8 Patients no longer go to the doctor solely with symp-
toms of an illness and rely on the doctor to prescribe the appropriate
134. See, e.g., Powell-Bullock, supra note 112 (stating that between 1997 and 1999,
physicians prescribed most frequently those drugs that were advertised the most); Why Drugs
Cost So Much, NEWSWEEK, Sept. 25, 2000, at 22, 29-30 ("[O]ne study notes that the 10 most
heavily advertised drugs accounted for 22 percent of the increase in drug spending between
1997 and 1998.").
135. Harrison & Jefferson, supra note 82, at 630-34 (providing a brief history of FDA
regulation of prescription drugs and summarizing its current regulatory scheme).
136. See Francis B. Palumbo & C. Daniel Mullins, The Development of Direct-to-Consumer
Prescription Advertising Regulation, 57 FOOD & DRUG L.J. 423 (2002) (providing an overview
of the FDA advertising regulations for prescription drugs); FOODAND DRUGADMIN., GUIDANCE
FOR INDUSTRY: CONSUMER-DIRECTED BROADCAST ADvERTISEMENTS 21 (1999), available at
http://www.fda.gov/cder/guidance/1804fnl.pdf.
137. Hall, supra note 82, at 469-70. The full quote reads:
Once an agency is captured by the industry it regulates, agency policy makers
and adjudicators have incentives to defer to the interests of the industry rather
than protecting the interests of consumers. While this article does not charge the
FDA with capture by the pharmaceutical industry, judicial review of companies'
actions independent of and supplemental to agency action guards against
capture by lessening the unilateral power of the agency, making capture less
attractive to the industry.
138. Fushman, supra note 82, at 1171 (discussing how patients go to doctors' offices with
names of prescription drugs and demanding prescriptions); see also THE HENRY J. KAISER
FAMILY FOUNDATION, IMPACT OF DIRECT-TO-CONSUMER ADVERTISING ON PRESCRIPTION DRUG
SPENDING 5 (2003), available at http://www.kff.org/rxdrugs/20011129a-index.cfm ("INlearly
a third (30%) of adults say they have talked to their doctor about a drug they saw advertised,
and 44% of those who talked to their doctor received a prescription for the medication they
asked about.").
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medications. Instead, patients increasingly go to the doctor asking for
specific drugs and stating that they have the particular symptoms
that fit that drug. 39 Thus, manufacturers can no longer claim that
they are unable to communicate with patients directly, for their
advertisements to consumers have proven quite successful.14
Further, as more and more drugs are created with pages of side
effects and contraindications, it is unreasonable to rely on physicians
to relay all of the information to patients.' It is especially unreason-
able within managed care because a physician's time with an
individual patient is decreased.'42 Thus, as the health care industry
and prescription drug industry change with the times and technology,
the law needs to follow the changes appropriately. The law needs to
reflect the fact that pharmaceutical manufacturers are now communi-
cating directly with consumers.4 3 Additionally, pharmacists provide
an additional link in the chain from manufacturer to patient, and
present another opportunity by which pharmaceutical manufacturers
can reach consumers to appropriately warn them of drugs' side effects
and contraindications.'"
If Wyeth had known that it would be held liable for any failure
to warn women of the risks and side effects of hormone replacement
therapy, it might have been more cautious in its clinical research on
the drug as well as in its promotion to physicians and consumers. It
is therefore possible that lives could have been saved. Instead, the
result is that women have been wronged for decades by the lack
of knowledge about hormone replacement therapy and its heavy
promotion by Wyeth.
The following sections demonstrate that if women can suffi-
ciently prove their cases, they should be able to hold Wyeth liable
for failure to warn them directly because hormone replacement
therapy actually fits into both the direct-to-consumer advertising
exception and the exception for contraceptives and contraceptive
devices. Hormone replacement therapy as a direct-to-consumer
advertising exception will be discussed first as expanding this
139. Fushman, supra note 82, at 1171 (describing also the phenomenon of"doctor shopping"
in which a patient goes to another doctor if the first does not give him the desired prescription
that he requested, and explaining that this is the reason that the European Economic
Community completely banned direct-to-consumer advertising of prescription drugs).
140. Perez v. Wyeth Labs. Inc., 734 A.2d 1245, 1255 (N.J. 1999). (remarking that
precription drug "advertising campaigns can pay off in close to billions in dividends").
141. Castagnera & Gerner, supra note 7, at 121.
142. See Perez, 734 A.2d at 1255-56.
143. Id. at 1245-57 (basing its decision on this underlying rationale).
144. See Castagnera & Gerner, supra note 7, at 123-24 (arguing that the burden to
adequately warn the patient of the drug's side effects and contraindications should rest on the
pharmacist).
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exception would have broader implications for holding future drug
manufacturers liable, as well as others engaged in extensive direct-
to-consumer advertising.
IV. HORMONE REPLACEMENT THERAPY AND DIRECT-TO-CONSUMER
ADVERTISING
Wyeth's Premarin and Prempro are exactly the type of drugs for
which the court in Perez v. Wyeth Laboratories Inc. did not intend for
the learned intermediary doctrine to still apply because of the
excessive direct-to-consumer advertising by the manufacturer. As
pointed out in Perez, when the learned intermediary doctrine was
devised to shield drug manufacturers from liability, they were not
directly advertising to consumers.'45 Today's marketplace has
changed as pharmaceutical companies inundate consumers with
advertisements for prescription drugs, 4 ' and Wyeth's promotion of
Prempro and Premarin is more the rule than the exception. Advertis-
ing was an essential part of Wyeth's business strategy for Prempro
and Premarin. 4 v It reached consumers through two advertising
methods: direct advertising to consumers and forming partnerships
with patient groups. In 2001, Wyeth spent $40 million on consumer
advertising alone for its two hormone replacement therapy drugs. 4 '
One direct-to-consumer sixty second television advertisement
depicted a woman stating, 'Menopause is complicated. Talking to my
doctor helped. For me, she prescribed Prempro. It's relieving my
uncomfortable symptoms and, along with calcium and exercise,
helping prevent osteoporosis."'149 Just as the Perez court found that
Wyeth had engaged in direct-to-consumer advertising through ads
in women's magazines, the same is true of advertisements for
hormone replacement therapy as Wyeth spent $30 million between
1997 and 1998 solely on direct-to-consumer magazine advertise-
ments for Premarin."' One study found that in a one-year study of
prescription drug advertisements in consumer magazines between
145. Perez, 734 A.2d at 1251-55.
146. Id. at 1251-53.
147. Albertson v. Wyeth Inc., 2003 WL 21544488, at *2 (Pa. Ct. C.P. July 8, 2003) ("[I1n
2000, [Wyeth spent] $37.9 million, on direct-to-consumer advertising for Prempro. In 2001,
Premarin became the first Wyeth brand to surpass $2 billion in annual sales.") (citations
omitted).
148. Michael Waldholz, Prescriptions: Patients Need to View Drug Ads with Some Healthy
Skepticism, WAUL ST. J., July 11, 2002, at D6.
149. Sandra Levy, First DTC Drug Ads of 2000 Promote A Wide Assortment, 144 DRUG
ToPics 120 (2000).
150. Janice Zoeller, The Top 200 Drugs, AM. DRUGGIST, Feb. 1999, at 41.
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1998 and 1999, sixty-three percent of all advertisements were drugs
that only treated symptoms. 5' Of that category of drugs, hormone
replacement therapy and allergy medications were the most frequent
advertisements.'52 The study also concluded that prescription drug
advertisements in magazines were most common in women's
magazines. 53 This is a marketing strategy in response to women's
preference to read about medical information in magazines so that
they can then take the advertisement with them when they see their
physician. 54
A magazine headline for Premarin that stated, "Everyday they
are learning more about estrogen loss. That's why I'm glad I take my
Premarin,"'15 and a headline for Prempro that stated, "Making Sense
Out of the Complexities of Menopause. Prempro Can Help,"' 6 are
precise examples of the vague statements that the Perez court was
concerned about being conveyed to consumers.'57 Furthermore, even
though hormone replacement therapy was only approved to treat the
side effects of menopause and prevent osteoporosis,' many physi-
cians believed that the therapy actually increased a woman's life
span at least in part because of Wyeth's marketing to physicians.'59
Wyeth also employed the marketing tactic of forming patient-
industry partnerships in which it would fund "disease awareness"
campaigns and make huge profits. 6 ° After studies revealed in 1988
that hormone replacement therapy helped to prevent osteoporosis,
Wyeth initiated a massive campaign to increase public awareness
of osteoporosis and to instruct women to discuss treatment with
their physicians.' Wyeth also provided financial support to the
Society for Women's Health Research (SWHR) for which it even
funded an elegant evening at the Ritz Carlton, but not without
turning the event from a campaign for women's health and research
into an advertisement for Wyeth.'62
151. Woloshin et al., supra note 124, at 1141.
152. Id. at 1142.
153. Id. at 1143.
154. Zoeller, supra note 150, at 41.
155. Woloshin et al., supra note 124, at 1141.
156. Levy, supra note 149, at 120.
157. Perez v. Wyeth Labs. Inc., 734 A.2d 1245, 1256-57 (N.J. 1999).
158. Albertson v. Wyeth Inc., 2003 WL 21544488, at *2 (Pa. Ct. C.P. July 8, 2003).
159. Waldholz, supra note 148.
160. BOB BURTON & ANDY ROWELL, CTR. FOR MEDIA & DEMOCRACY, DISEASE MONGERING
5 (2003) available at http://www.prwatch.org/prwissues/2003Q/monger.html.
161. Zoeller, supra note 150, at 41.
162. Alicia Mundy, Hot Flash, Cold Cash: How a Once-Respected Women's Group Went
Through the Change - With the Help of Drug Industry Money, WASH. MONTHLY, Jan./Feb.
2003, at 35; see also BURTON & ROWELL, CTR. FOR MEDIA & DEMOCRACY, supra note 160, at 5.
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Wyeth's direct-to-consumer advertisements and disease part-
nership campaigns certainly paid off, as it reaped huge profits from
its two drugs, Prempro and Premarin. Between 1990 and 1995,
Premarin was the prescription drug most frequently given in the
U.S. 6 3 By 2001, Prempro sales alone reached approximately $900
million,"M with 22.3 million prescriptions written per year. 65 One
study found that 92% of gynecologists routinely offered hormone
replacement therapy to their menopausal patients.'66 A study
comparing prescribing patterns of hormone replacement therapy in
the United States with Europe found that the former was the
greater user.6 7 This could at least be due in part to Wyeth's heavy
advertising to physicians and consumers of hormone replacement
therapy in the United States. 168 Wyeth bombarded physicians and,
more importantly, consumers, with advertisements for Premarin
and Prempro, just as the Perez court found that Wyeth had inun-
dated consumers with advertisements for the Norplant System.
169
Thus, the analysis in Perez, dismissing the premises for the
learned intermediary doctrine when the manufacturer engages heavily
in direct-to-consumer advertising, applies to hormone replacement
therapy as well. The Perez court stated that the fear of undermining
the doctor-patient relationship, an original reason for the learned inter-
mediary doctrine, no longer exists with direct-to-consumer advertising
for two reasons. 7 ° The advertisements themselves are already under-
mining the relationship, and the success of the advertisements
demonstrates that patients are taking an active role in their health
care decisions.' 7 ' Just as this analysis was particularly true with the
163. Coolidge, supra note 35.
164. Melody Petersen, Survey Halted, Drug Makers Seek to Protect Hormone Sales, N.Y.
TIMES, July 17, 2002, at Cl.
165. KATHRYN I.C. HUANG & MEGAN E. VAN AELSTYN, ARTHUR W. PAGE SOC Y, WYETH
PHARMACEUTICALS: PREMARIN AND PREMPRO AND HORMONE REPLACEMENT THERAPY (A) 6
(2003), available at http://www.awpagesociety.com/resources/case._studies/wyeth-a-case.pdf.
166. Boris Kaplan et al., Gynecologists' Trends and Attitudes Toward Prescribing Hormone
Replacement Therapy During Menopause, 9 MENOPAUSE 354, 355-59 (2002).
167. Jacqueline V. Jolleys & Frede Olesen, A Comparative Study of Prescribing of Hormone
Replacement Therapy in USA and Europe, 23 MATURITAS 47 (1996) ("Sales of HRT as a proxy
for both prescribing and consumption fall into three groupings: the USA being the highest;
the UK and Scandinavian countries are in the middle group; continental Europe has low sales
in terms of women treatment years of HRT, although France is approaching the middle
group.").
168. See HUANG & VAN AELSTYN, ARTHUR W. PAGE SOC'Y, supra note 165, at 5-6 (describing
the extensive advertising of Wyeth's hormone replacement therapy); Waldholz, supra note 148
(discussing Wyeth's successful advertising of Premarin and Prempro).
169. See Perez v. Wyeth Labs. Inc., 734 A.2d 1245, 1248 (N.J. 1999) (referring to Wyeth's
advertising campaign as "massive").
170. Id. at 1256.
171. Id.
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Norplant devices in Perez, it is true with hormone replacement therapy
because of the patient's active role in the decision to use the drugs.
Wyeth certainly can not be said to "lack effective means"'72 to communi-
cate with the public as it has spent so much money on television and
magazine advertisements for Premarin and Prempro.' 7 ' Perez further
concluded that direct-to-consumer advertisements should not preclude
patients from holding pharmaceutical companies liable, particularly
with respect to a lifestyle drug, such as the Norplant device.' 74 This is
because consumers should receive more protection from drugs that are
not medically necessary.'75 This analysis also extends to hormone
replacement therapy, as it simply improves a woman's quality of life by
lessening the side effects of a natural stage in a woman's life. After the
WHI Study, doctors recommended that women adopt healthier
lifestyles by eating and drinking more healthfully, particularly foods
with more calcium and vitamin D, having bone density scans, exercis-
ing, and stopping smoking.' These recommendations provide further
evidence that hormone replacement therapy is a lifestyle drug because
a woman can alleviate menopausal symptoms by changing her lifestyle.
Finally, as will be discussed below, one of the reasons that courts
developed the exception to the learned intermediary doctrine for oral
contraceptives was because they were heavily marketed to women.
Thus, the impact of direct-to-consumer advertising on women's usage
was a factor in the oral contraceptives analysis.
V. HORMONE REPLACEMENT THERAPY WITHIN THE ORAL
CONTRACEPTIVES EXCEPTION
Although the direct-to-consumer advertising exception to the
learned intermediary doctrine should apply because of heavy advertis-
ing and promotion by Wyeth, the reality is that only the Supreme
Court of New Jersey Court has adopted the exception in Perez v. Wyeth
Laboratories Inc. There may, however, be a greater possibility of
getting around the learned intermediary doctrine by expanding the
exception for oral contraceptives to include hormone replacement
172. Id. at 1255 (quoting Lars Noah, Advertising Prescription Drugs to Consumers:
Assessing the Regulatory and Liability Issues, 32 GA. L. REv. 141, 158 (1997)).
173. See Waldholz, supra note 148; Andrew McMains, Shop Sought for Revamped Drug:
ER Drug Premarin Gets New Formula, ADWEEK.COM, Aug. 5, 2002, http://www.adweek.com/
aw/searchlarticle._display.jsp?vnucontentjid=1592521.
174. Perez, 734 A.2d at 1257.
175. Id. at 1256.
176. Caren G. Solomon & Robert G. Dluhy, Rethinking Postmenopausal Hormone Therapy,
348 NEW ENG. J. MED. 579 (2003).
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therapy, as several courts have recognized the oral contraceptives
exception and some states even include intrauterine devices (IUDs).
Much of the court's rationale in Stephens v. G.D. Searle & Co.
about oral contraceptives also applies to hormone therapy drugs. First,
as with oral contraceptives,177 the decision to take hormone replace-
ment therapy is made by the female patient after consultation with
her doctor rather than being based upon a doctor's diagnosis. 7
Menopause is not a disease for which a woman goes to her physician
seeking a cure; menopause is a natural phase in a woman's reproduc-
tive life cycle.'79 As a natural stage, there are natural symptoms that
are manifested in the woman's body. A woman may decide which
method is best for her to alleviate the uncomfortable symptoms.
Nonetheless, there are alternatives to hormone replacement therapy
for coping with menopause, just as there are means to prevent
pregnancy other than oral contraceptives. A woman may decide to
take natural soy and herbs in place of a prescription, or a woman may
decide to stay active, live a healthy lifestyle, and eat low-fat, healthy
foods."S There are other alternatives for treating osteoporosis as well.
A woman may take calcium supplements'8 ' or even the prescription
drug Fosamax instead of hormone replacement therapy. 2 If a woman
chooses to take hormone replacement therapy over the other options,
she must still decide among the various brand names, including
alternatives to Wyeth's Prempro, such as Eli Lilly's Evista.'" While a
physician may inform a patient's decision, the choice between hormone
replacement therapy and the alternatives is one which the woman
must ultimately make."s The woman herself must balance the pros
of hormone replacement therapy, such as the prevention of osteo-
porosis and the alleviation of symptoms including tissue dryness,
mood swings, and night sweats, with the treatment's cons, such as
possible increased risk of breast cancer.' Just as a woman's decision
to take oral contraceptives alters conception and child-bearing (natural
177. Stephens v. G.D. Searle & Co., 602 F. Supp. 379, 380 (E.D. Mich. 1985).
178. Harvard Medical School, Hormone Replacement Therapy: Weighing the Benefits and
Risks, 22 HARVARD HEALTH LETTER 1 (1997).
179. Id.
180. June Rogers, Menopause Without Hormones, 70 CHATELAINE 35, 37 (1997).
181. Harvard Medical School, supra note 178, at 1.
182. Petersen, supra note 164.
183. Id.
184. Harvard Medical School, supra note 178, at 3.
185. Id. Only the possible risk of breast cancer is listed because at the time the plaintiffs
who filed lawsuits against Wyeth decided to take Wyeth's prescription hormone replacement,
this was the major concern as the results of the WHI Study sponsored by the NIH had not yet
been released. As a result of the study, a woman opting for hormone replacement therapy
today must weigh the pros against a longer list of cons.
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processes of the female reproductive system), the decision to use
hormone replacement therapy is a decision to alleviate the side effects
of the natural process of menopause (a later phase of the female
reproductive cycle). Both hormone replacement therapy and oral
contraceptives are taken by women as quality of life drugs, and patient
choice plays a large role in the prescription of both."s
Courts upholding the oral contraceptives exception to the learned
intermediary doctrine have also based their decision on the drug's
marketing. Heavy advertising to consumers by pharmaceutical
companies has induced many women to believe that oral contraceptives
are the best form of contraception, so they request them from their
physicians."8 7 As a result of such "zealous marketing practices,"'88 as of
2002, 11.6 million women were using oral contraceptives." 9 That is the
equivalent of just less than twenty percent of women of child-bearing
age in the United States.190 If twenty percent of women is the result of
"zealous" advertising, then the marketing of hormone replacement
therapy has been incredibly "zealous." As of 1995, thirty-eight percent
of postmenopausal women between the ages of fifty and seventy-four
were using hormone replacement therapy.1 9' As of the summer of 2002,
fifteen million women were receiving prescriptions for hormone
replacement therapy a year.'92 Furthermore, when one considers that
the recent WHI studies revealed unexpected risks associated with
hormone replacement therapy, the marketing strategies must have
been quite extraordinary. As this note has discussed, for years Wyeth
inundated women with advertisements that both Premarin and
Prempro alleviated the symptoms of menopause and prevented
osteoporosis.'93 Just as the pharmaceutical advertisements for oral
contraceptives were successful, Wyeth's advertising campaign was
equally successful in recruiting physicians to prescribe hormone
replacement therapy.
186. See Stephens v. G.D. Searle & Co., 602 F. Supp. 379, 380 (E.D. Mich. 1985) ('The focus
with oral contraceptives is on patient choice.").
187. Id.
188. Id.
189. WiLLIAM D. MOSHER ET AL., CTRS. FOR DISEASE CONTROL AND PREVENTION USE OF
CONTRACEPTION AND USE OF FAMILY PLANNING SERVICES IN THE UNITED STATES: 1982-2002
1 (2004).
190. See THE ALAN GUTTMACHER INST., CONTRACEPTIVE USE, http://www.agi-usa.org/pubs/
fbcontr use.html (stating that in 2003 there were 62 million women in the United States of
child-bearing age).
191. Nancy L. Keating et al., Use of Hormone Replacement Therapy by Postmenopausal
Women in the United States, 130 ANNALS OF INTERNAL MEDIC. 545, 549 (1999).
192. Adam Hersh et al., National Use of Postmenopausal Hormone Therapy, 291 JAMA 47
(2004).
193. HUANG & VAN AELSTYN, ARTHUR W. PAGE SOC'Y, supra note 165, at 5-6.
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As is the case with oral contraceptives, hormone replacement
therapy drugs have been taken by women for extended periods of time
similar to oral contraceptives. An exception to the learned intermediary
doctrine for oral contraceptives was justified at least in part due to this
extended usage. Doctors have prescribed hormone replacement
therapies for various lengths of time, from only five or ten years to
indefinite amounts of time.194 One study showed that seventy percent
of American gynecologists prescribe hormone replacement therapy for
indefinite periods of time while sixteen percent stop prescribing it
after ten years.'95 This is despite the fact that hot flashes, a common
symptom of menopause for which hormone replacement therapy is
taken, usually subside after five years."
Extended use of oral contraceptives created a different doctor-
patient relationship because a woman could refill her prescription
without seeing her physician for long periods of time.'97 Physicians
commonly prescribe oral contraceptives after seeing the patient once
and then only annually. 9 ' As a result, physicians only minimally
monitor side effects of oral contraceptives.'99 In some cases, the
relationship is even more attenuated because manufacturers send the
birth control in bulk shipments directly to birth control clinics where
they are given without prescriptions.2" The concern that physicians are
not able to monitor the drugs' side effects as a result of only annual
visits is not a serious concern with hormone replacement therapy. Nor
is there a concern with hormone replacement therapy being sent in
bulk to clinics to be given without a physician.
Although one of the reasons the court in Stephens v. G.D. Searle &
Co. abandoned the learned intermediary doctrine for oral contracep-
tives was the minimal nature of the physician-patient relationship,2 '
this requirement has become arguably less important since the Eighth
Circuit expanded the oral contraceptives exception to include
intrauterine devices (IUDs). 22 Instead of focusing on the minimal
nature of the physician-patient relationship, the Eighth Circuit focused
on the role of the physician in a patient's decision-making process to
194. Kaplan et al., supra note 166, at 356.
195. Id.
196. Sally E. McNagny, Prescribing Hormone Replacement Therapy for Menopausal
Symptoms, 131 ANNALS OF INTERNAL MEDIC. 605, 606 (1999).
197. Stephens v. G.D. Searle & Co., 602 F. Supp. 379, 381 (E.D. Mich. 1985).
198. Odgers v. Ortho Pharm. Corp., 609 F. Supp. 867 (E.D. Mich. 1985); Stephens, 602 F.
Supp. at 379; MacDonald v. Ortho Pharm. Corp., 475 N.E.2d 65 (Mass. 1985)
199. Odgers, 609 F. Supp. at 867; Stephens, 602 F. Supp. at 379.
200. Taurino v. Ellen, 579 A.2d 925 (Pa. Super. Ct. 1990).
201. Stephens, 602 F. Supp. at 380-81.
202. Hill v. Searle Labs., 884 F.2d 1064, 1070-71 (8th Cir. 1989).
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undergo contraception with an intrauterine device.2°3 Even though a
device must be implanted and monitored by a physician, the patient
rather than the physician decides to implant the device.2 °4 Similarly,
although a patient must see a physician regularly when taking
hormone replacement therapy,2"5 the decision to use hormone replace-
ment therapy to alleviate the symptoms of menopause is a personal
decision made by the woman after evaluating the alternatives.0 6
Additionally, for both oral contraceptives and hormone replace-
ment therapy, there exists a public policy interest in preventing
patients from refusing to take prescription drugs after reading the
warnings, but patients should be informed of the range of options.20 7 A
woman should be informed about the drug's risks and side effects so
she is better able to weigh the therapy against the alternatives.2 ' If
knowing all of the risks of hormone replacement therapy leads a
woman to decide not to use the drugs, then she is not harmed by that
decision.
Finally, some courts have recognized an exception to the learned
intermediary doctrine for oral contraceptives since the FDA already
mandates that manufacturers include patient package inserts with the
distribution of all oral contraceptives.2 9 The FDA similarly mandates
that manufacturers directly warn consumers of estrogens, using
patient package inserts.210 The underlying rationale for this is that the
learned intermediary doctrine is meaningless if the FDA requires
direct communication from the manufacturer to the patient.21' The
requirements for patient inserts for oral contraceptives were promul-
gated because oral contraceptives are taken by large numbers of
women, who are generally healthy, for long periods of time because
they choose to prevent pregnancy.212 Similarly, the FDA promulgated
a regulation in 1990 requiring patient package inserts to be distributed
203. Id. at 1071.
204. Id.
205. McNagny, supra note 196, at 605.
206. Harvard Medical School, supra note 178, at 1.
207. See Odgers v.Ortho Pharm. Corp., 609 F. Supp. 867 (E.D. Mich. 1985).
208. See Harvard Medical School, supra note 178, at 1.
209. Although this note considers the FDA regulation of patient package inserts as one
factor as to why oral contraceptives are excluded in some jurisdictions from the learned
intermediary doctrine, some scholars consider the exception for oral contraceptives separate
from the exception for drugs which have FDA-mandated patient warnings. See, e.g., Ausness,
supra note 10, at 111-12; Andrea M. Greene, Pharmaceutical Manufacturers' Liability for
Direct Marketing and Over-Promotion of Prescription Drugs to Product Users, 26 AM. J. TRIAL
ADVOC. 661, 670-71 (2003).
210. 21 C.F.R. § 310.515 (2005).
211. Ausness, supra note 10, at 113.
212. Statement of Policy Concerning Oral Contraceptive Labeling Directed to Users, 35
Fed. Reg. 9001, 9002 (June 11, 1970).
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to all patients with each package of hormone replacement therapy.213
In 1999, the FDA even issued a draft guidance for the labeling of
estrogens for the pharmaceutical industry.214
The FDA's recent changes to its labeling requirements for
hormone replacement therapy drugs further demonstrate that
because hormone replacement therapy is already heavily regulated
by the FDA, it should also be excluded from the learned intermediary
doctrine. As a result of the WHI Study, the FDA is requiring new
safety changes to the labels of all products that contain either
estrogen alone or a combination of estrogen and progestin.215 The new
labeling requirements include new physician prescribing information,
new leaflets with updated information for patients, and new warning
labels on the outside of the prescription boxes.216 The boxed warning is
the highest level of FDA warning for prescription drugs.21 7 It includes
results of the WHI Study, a statement that estrogens and progestins
should not be used to prevent cardiovascular disease, and a statement
that physicians should only prescribe estrogens and progestins at the
lowest effective doses for the shortest possible durations.2 '
CONCLUSION
The class actions against Wyeth for failure to warn patients of
the risks of its hormone replacement therapy drugs present ripe
opportunities for courts to chip away at the out-dated learned inter-
mediary doctrine, either by recognizing the New Jersey Supreme
Court's direct-to-consumer advertising exception or by expanding
the oral contraceptives exception. Although recognition of the direct-
to-consumer advertising exception would be more beneficial for
consumers, it is the less likely of the two due to the plethora of drugs
213. 21 C.F.R. § 310.515 (2005).
214. See CTR. FOR DRUG EVALUATION AND RESEARCH, GUIDANCE FOR INDUSTRY: LABELING
GUIDANCE FOR NONCONTRACEPTIVE ESTROGEN DRUG PRODUCTS FOR THE TREATMENT OF
VULVAR AND VAGINAL ATROPHY SYMPTOMS - PRESCRIBING INFORMATION FOR HEALTH CARE
PROVIDERS AND PATIENT LABELING, REVISION ONE (2004), available at www.fda.gov/cder/
guidance/5670dft.pdf (providing an introduction of the draft guidance first issued in
September 1999 and detailing the new draft guidelines issued on February 3, 2003).
215. Joan Stephenson, FDA Orders Estrogen Safety Warnings: Agency Offers Guidance for
HRT Use, 289 JAMA 537, 538 (2003).
216. FOOD AND DRUG ADMIN., FDA APPROVES NEW LABELS FOR ESTROGEN AND ESTROGEN
WITH PROGESTIN THERAPIES FOR POSTMENOPAUSAL WOMEN FOLLOWING REVIEW OF WOMEN'S
HEALTH INITIATIVE DATA 1 (2003), available at http://www.fda.govfbbs/topics/NEWS/2003/
NEW00863.html.
217. Stephenson, supra note 215, at 537-38.
218. Id. at 537-38.
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now marketed to consumers which would be affected. Thus, expand-
ing the oral contraceptives exception to include hormone replacement
therapy presents reluctant courts with the most palatable means of
chiseling away at the learned intermediary doctrine.
How many more hormone replacement therapy-like incidences will
it take before society has had enough and finally decides to hold
pharmaceutical companies accountable for their products just as it
holds accountable manufacturers of other products?
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